Wang, J., Chang, Y., Liu, X., Yu, W., Jiang, H., Huang, X., . . . Gong, L. Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: Efficacy, safety, and biomarker analysis of a phase II, single-arm trial. BMJ Publishing Group.
Chicago Style (17th ed.) CitationWang, Jing, et al. Sintilimab Plus Decitabine for Higher-risk Treatment-naïve Myelodysplastic Syndromes: Efficacy, Safety, and Biomarker Analysis of a Phase II, Single-arm Trial. BMJ Publishing Group.
MLA (9th ed.) CitationWang, Jing, et al. Sintilimab Plus Decitabine for Higher-risk Treatment-naïve Myelodysplastic Syndromes: Efficacy, Safety, and Biomarker Analysis of a Phase II, Single-arm Trial. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.